Send This Page By E-mail
Print this page
The Importance of High-Density Lipoprotein and High-Density Lipoprotein Cholesterol Levels in Cardiovascular Health: A Clinical Overview
Released: 12-06-04
Expires: 12-06-06
Jointly sponsored by:
 and 
The FCG Institute for Continuing Education and IntraMed Scientific Solutions gratefully acknowledge an educational grant from AstraZeneca Pharmaceuticals LP in support of this continuing medical education activity.
Overview
There has been an increased interest over the last 30 years in high-density lipoprotein (HDL) and high-density lipoprotein cholesterol (HDL-C) levels and their impact on health. Current clinical interest has focused on HDL-levels in the context of coronary artery disease (CAD) risk and risk reduction. There is also indication of other areas in which the effects of HDL are being investigated. An overview of the clinical observations, evaluations, and therapies associated with HDL and HDL-C levels will be reviewed.
Goal
To provide health-care professionals with an evidence-based clinical overview of the importance of HDL and HDL-C levels in cardiovascular health.
Target Audience
The Importance of High-Density Lipoprotein and High-Density Lipoprotein Cholesterol Levels in Cardiovascular Health: A Clinical Overview is intended for physicians, pharmacists, nurses and nurse practitioners with an interest in dyslipidemia.
Learning Objectives
Following completion of this activity, participants should be able to:
- Define the relationship between high-density lipoprotein cholesterol (HDL-C) and risk for coronary artery disease (CAD)
- Determine the conditions/activities related to low HDL-C levels
- Recognize the potential role of pharmacological interventions in raising HDL-C in high-risk patients
- Apply the National Cholesterol Education Program Adult Treatment Program III recommended therapeutic strategies to raise levels of HDL-C in individuals at risk for CAD
Accreditation and Credit Designation Statements
CME
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The FCG Institute of Continuing Education and IntraMed Scientific Solutions. The FCG Institute for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.
The FCG Institute for Continuing Education designates this educational activity for a maximum of 2.0 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
The American Medical Association has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA category 1 credit.
CPE
 |
The FCG Institute for Continuing Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned the Universal Program Number 086-999-04-026-H01 and has been approved for 2.3 contact hours (0.23 CEUs). |
CNE
The FCG Institute for Continuing Education is an approved provider of continuing nursing education by Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. This activity is certified for 2.3 contact hours.
CNPE
This program has been approved for 2.3 contact hours of continuing education by the American Academy of Nurse Practitioners. Program ID 0412484.
How to Receive CE Credit
To receive credit for this CE activity, you must review the entire slide kit, complete an evaluation and credit request form, and score 70% or higher on the posttest. Forms must be submitted by 12-6-06 [2 years from active date] to: The FCG Institute for Continuing Education-2326-1, 1140 Welsh Road, Suite 210, North Wales, PA 19454; or Fax to: 215-412-9686. A certificate will be mailed to you in 4-6 weeks of our receipt of the completed 2-page form. There is no fee associated with this activity and it should take approximately 2 hours to complete.
To access the presentation, posttest, and CE Credit form, please follow the links at the bottom of this page to view and/or download.
Release and Expiration
This activity was released on 12/6/04 and will expire on 12/6/06.
Unlabeled or Investigational Use Statement
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the US Food and Drug Administration (FDA). The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off label or investigational uses (any use not approved by the FDA) of products or devices.
The FCG Institute for Continuing Education, the faculty, and AstraZeneca Pharmaceuticals LP do not endorse the use of any product outside of the FDA-labeled indications. Healthcare professionals should not utilize the procedures, products, or diagnostic techniques discussed during this activity without evaluation of their patients for contraindications or dangers of use.
Disclosure Statement
It is the policy of the FCG Institute for Continuing Education to ensure independence, balance, objectivity, and scientific rigor and integrity in all its CE activities. Faculty must disclose to the participants any significant relationships with commercial companies whose products or devices may be mentioned in faculty presentations or with the commercial supporter of this activity. Disclosure information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations. Faculty disclosure statements can be found with their biographical sketches.
Faculty
Dr. Roger Ilingworth ,Dr. Jeffrey G. Shanes, and Dr. Peter P. Toth served as the course directors for this slide kit.
Faculty Disclosure Statements
Dr. Illingworth has disclosed that he has received grants and research support from AstraZeneca Pharmaceuticals LP. He has participated in the Speakers Bureau for Kos Pharmaceuticals, Inc., Merck & Co, Inc., Pfizer, Inc., Schering-Plough Corporation and has acted as a consultant for AstraZeneca Pharmaceuticals LP, and Sankyo Pharma.
Dr. Shanes has disclosed that he has received grants/research support and honoraria from AstraZeneca Pharmaceuticals LP.
Dr. Toth has disclosed that he has served on a Speakers Bureau for AstraZeneca Pharmaceuticals LP; Kos Pharmaceuticals, Inc.; Merck & Co., Inc.; and Pfizer Inc. He has also served as a consultant for AstraZeneca Pharmaceuticals LP and Merck & Co., Inc.
Click here to verify that you have read and accept the CE Information and Terms above
Presentation
Click here to view presentation
Click here to download presentation
Posttest and CE Credit Form
Click here to download
Please note: you may have to select the refresh button on your Web browser to view the Posttest and the CE Credit Form.
CE Activity Viewing Requirements
You must be a registered cvspectrum.org user to review and/or receive credit for this CE Activity. Registered users, login now by clicking here. If you are not already a registered member of the cvspectrum.org community and would like to access this CE Activity, Register Now
|